Arkiv

• 2020-02-05

  NeoDynamics AB (publ) full-year report 2019

  Summing up a productive 2019 Weiterlesen

• 2020-02-03

  A clinical study performed at Karolinska Hospital with NeoDynamics’ new biopsy system, NeoNavia, has been accepted as an abstract by the Society for Breast Imaging (SBI) in the US.

  Associate professor Edward Azavedo has performed a retrospective study at Karolinska Hospital, where he analyzed tissue samples using NeoDynamics’ new biopsy system, NeoNavia. An abstract with the initial study results has been accepted by SBI for presentation at their annual meeting in Denver, April 16-19, 2020. Weiterlesen

• 2020-01-28

  NeoDynamics AB (publ) receives notification of granted patent on biopsy instrument in China

  The expected announcement from the Chinese patent authority means that NeoDynamics´ unique biopsy device with front-loaded needle and integrated trocar, an important component of the NeoNavia® biopsy system is approved. The patent increases the protection of the NeoNavia biopsy system, which further strengthens the competitiveness. Weiterlesen

• 2019-11-27

  NeoDynamics signs manufacturing agreement for NeoNavia

  NeoDynamics has signed an agreement with a world class contract manufacturer to prepare market introduction of the company’s new breast cancer biopsy system NeoNavia® and scale up production of the new biopsy probe models.  Weiterlesen

• 2019-11-21

  NeoDynamics AB (publ) Third quarter Jul-Sep 2019

  During the third quarter NeoDynamics developed according to plan. After the end of the quarter the new version of NeoDynamics biopsy system NeoNavia received regulatory approval in the EU and attracted great interest at the annual British radiology congress. The convertible loan was subscribed to an amount of ca SEK 15 million. Weiterlesen

• 2019-11-05

  For the first time in UK, a wider audience can get first-hand experience of the NeoNavia® micropulse biopsy system for breast cancer

  During the annual meeting of the British Society of Breast Radiology (BSBR) on 3-5th November in Bristol, radiologists get to gain first-hand experience using the innovative micropulse technology in meat models via a series of hands-on workshops arranged by NeoDynamics Weiterlesen

• 2019-10-29

  NeoDynamics receives regulatory approval for new breast cancer biopsy system

  NeoDynamics today received confirmation from Intertek (Notified Body) that the improved version of the new system for breast cancer biopsy, NeoNavia, is accepted as an update to the already EU approved study version. The upgraded pulse biopsy system including three needle types, is added to the product list on the company’s EC certificate. Weiterlesen

• 2019-09-16

  NeoDynamics recruits a country manager for Germany, Switzerland and Austria

  Renate Reiss takes over as Country Manager for NeoDynamics in the German-speaking countries in the EU, starting on 15 October. Renate has a broad international experience in product launches, from leading roles in the pharmaceutical industry. She will be responsible for the launch of NeoNavia, a brand new system for breast cancer tissue diagnosis. Weiterlesen

• 2019-08-28

  NeoDynamics has secured financing through the issue of convertibles and calls for an Extraordinary General Meeting

  The Board of Directors of NeoDynamics AB (publ) ("NeoDynamics") or ("The Company") has decided to propose an issue of convertibles of up to SEK 15 million to strengthen the Company's cash and secure capital requirements prior to the start of production and clinical trials. The Board has therefore decided to convene an Extraordinary General Meeting on September 16. See attached notice (Swedish language) Weiterlesen

• 2019-08-28

  NeoDynamics Half-year report 2019

  Approaching the market – registration in focus Weiterlesen

• 2019-08-15

  New date for NeoDynamics semi-annual report 2019

  The Board of Directors of NeoDynamics AB (publ) has decided a new date for the publication of the semi-annual report 2019. The Report will be published on August 28, 2019.  Weiterlesen

• 2019-05-22

  NeoDynamics AB (publ) invests in biopsy instrument for more effective sampling of suspected skin cancer

  NeoDynamics AB (publ) starts a joint venture, for the development of a new biopsy instrument for more effective tissue sampling of suspected skin cancer. Weiterlesen

• 2019-05-21

  NeoDynamics AB (publ) - Quarterly report January-March 2019

  First quarter developed according to plan. Started development of a biopsy marker Weiterlesen

• 2019-04-26

  NeoDynamics AB (publ) receives advance notice from U.S. Patent Office for a granted biopsy instrument patent

  NeoDynamics AB (publ) has received notification, a “Notice of Allowance”, from the US Patent Authority that patent will be granted provided that the grant fee is paid Weiterlesen

• 2019-04-10

  New breast biopsy device is evaluated at Karolinska University Hospital in Stockholm

  NeoDynamics has received ethical approval to retrospectively analyse data from biopsy procedures that were performed using the NeoNavia biopsy system at Karolinska University Hospital in Stockholm (This pressrelease was originally published in a Swedish version on 8 April, 2019) Weiterlesen

• 2019-02-21

  Year-end report 2018 - NeoDynamics

  The First Year-end report from NeoDynamics Weiterlesen

• 2019-02-18

  New Swedish technology for breast cancer diagnosis tested by leading experts in Germany

  NeoDynamics´ German multi center study (PULSE)[1] (http://file///G:/Pressmeddelanden/SVE_PM_AwoGyn_20190218_klar.docx#_ftn1) was presented for 150 participants at the annual AWOgyn-meeting Weiterlesen

• 2018-12-07

  NeoNavia commercial version fully integrated according to plan

  NeoDynamics commercialization of its innovative biopsy system NeoNavia is progressing according to plan. The development team has received the awaited fully integrated biopsy system prototypes and the final evaluation and optimization is now well under way. Weiterlesen

• 2018-12-07

  First day of trading in NeoDynamics’ shares and warrants on Spotlight Stock Market

  Today, on December 7, 2018, the trading in NeoDynamics AB (publ)’s (”NeoDynamics”) shares and series TO 1 warrants starts at Spotlight Stock Market. The share is traded under the ticker “NEOD” and the share’s ISIN code is SE0011563410. The series TO 1 warrants are traded under the ticker “NEOD TO 1” and the warrant’s ISIN code is SE0011725605. Weiterlesen

• 2018-11-19

  NeoDynamics’ issue of units prior to planned listing on Spotlight Stock Market fully subscribed

  On November 14, 2018, the subscription period for NeoDynamics AB (publ) (”NeoDynamics”) issue of units of initially approx. SEK 50.5 million prior to listing on Spotlight Stock Market (“Spotlight”) was completed. The issue of units was subscribed to approx. SEK 44.9 million, equating to a subscription ratio of approx. 89 percent prior free guarantee subscription of approx. SEK 5.6 million from the company’s principal shareholder. Through the issue of units, NeoDynamics is allocated approx. SEK 50.5 million before issue costs, which amounts to approx. SEK 2.5 million. Through the issue of units, NeoDynamics will receive approx. 750 new shareholders. The first day of trading on Spotlight is expected to be December 7, 2018. Through the completed issue of units, the company has been given the necessary capital to continue its development of NeoNavia towards a commercial version and market launch. Weiterlesen

• 2018-11-12

  NeoDynamics participates on Stora Aktiedagen and in a Live Session with Småbolagsjakten today

  NeoDynamics AB (publ) (”NeoDynamics”) – with a new patented micropulse technology to simplify and improve the precision in biopsy procedures – will participate on Stora Aktiedagen in Gothenburg today, on the 12th of November 2018. CEO Anna Eriksrud and CFO Jörgen Vrenning will present the company and its plans for the future. Furthermore, the company will also participate in a Live Session with Småbolagsjakten today. For more details, see below. Weiterlesen

• 2018-11-06

  NeoDynamics participates in investor meetings during the IPO

  NeoDynamics AB (publ) (”NeoDynamics”) – with a new patented micropulse technology to simplify and improve the precision in biopsy procedures – will participate in investor meetings in Stockholm, Copenhagen and Gothenburg between the 7th – 12th of November 2018 Weiterlesen

• 2018-11-06

  NeoDynamics introduces NeoNavia®, a micropulse biopsy system, to a wider audience in the UK

  Press release November 6, 2018 NeoDynamics introduces NeoNavia®, a micropulse biopsy system, to a wider audience in the UK at the British Society of Breast Radiology Annual Scientific Meeting 2018 in Newcastle Weiterlesen

• 2018-11-01

  New technology from NeoDynamics approved for study in Germany

  German multi-center study (“PULSE”) receives ethical approval and endorsement of the German Society of Gynecology and Obstetrics Weiterlesen

• 2018-10-31

  The subscription period in NeoDynamics’ issue of units prior to planned listing on Spotlight Stock Market begins today

  NeoDynamics AB (publ) (”NeoDynamics”) – with a new patented micropulse technology to simplify and improve the precision in biopsy procedures – today announces the start of the subscription period in the company’s issue of units prior to planned listing on Spotlight Stock Market (“Spotlight”). A fully subscribed issue of units will initially provide the company with approximately SEK 50.5 million before issue costs and a further SEK 25.3 million in case all of the attached free series TO 1 warrants are exercised. NeoDynamics has secured approximately 73 percent of the initial issue amount through subscription commitments and a gratuitous guarantee subscription.  Weiterlesen

• 2018-10-30

  NeoDynamics AB (publ) announces approval on passportation of prospectus

  NeoDynamics AB (publ) (”NeoDynamics”) – with a new patented micropulse technology to simplify and improve the precision in biopsy procedures – hereby announces approval on passportation of the prospectus. Weiterlesen

• 2018-10-29

  NeoDynamics AB (publ) publishes prospectus and enters agreement on additional subscription commitment

  NeoDynamics AB (publ) (”NeoDynamics”) – with a new patented micropulse technology to simplify and improve the precision in biopsy procedures – today publishes a prospectus for the upcoming issue of units, in which the subscription period starts on the 31st of October, 2018. The prospectus is available on the websites of the NeoDynamics (www.neodynamics.com) and Sedermera Fondkommission (www.sedermera.se). The prospectus is also available at www.spotlightstockmarket.com. Teaser and subscription form will be published on the webpages above at the start of the subscription period. Furthermore, NeoDynamics hereby announces that an additional party, Gryningskust Holding AB, has given a subscription commitment of SEK 1 999 980,00, of which SEK 999 990,00 constitutes bridge finance. The total commitments in the issue of units is therefore approximately SEK 37 million, of which subscription commitments amounts to SEK 31 million (of which approximately SEK 15.5 million constitutes bridge finance) and SEK 6 million is a free top-down guarantee subscription from the company’s principal shareholder. NeoDynamics has thus beforehand agreed on a total of 73 percent of the initial issue or units through subscription commitments and free top-down guarantee subscription. Before the additional subscription commitment, the equivalent number was 69 percent. Weiterlesen

• 2018-10-25

  NeoDynamics AB (publ) approved for listing on Spotlight Stock Market

  NeoDynamics AB (publ) (”NeoDynamics”) – with a new patented micropulse technology to simplify and improve the precision in biopsy procedures – today announces that the company has been approved for listing at Spotlight Stock Market (”Spotlight”). The approval is given under the condition that the company raises the minimum limit and provided that Spotlight’s ownership requirements are met. NeoDynamics also announces that the subscription period in the upcoming issue of units will commence on Wednesday the 31st of October and conclude on the 14th of November 2018. A fully subscribed issue of units will initially provide the company with approximately SEK 50.5 million before issue costs and a further SEK 25.3 million in case all of the attached free series TO 1 warrants are exercised. NeoDynamics has secured approximately 70 percent of the planned issue amount thought subscription commitments and a gratuitous guarantee subscription. The company’s principal shareholder is also lead investor in the issue of units through both subscription commitments and a gratuitous guarantee subscription. The funds from the issue of units is planned to finance the final development stage of the commercial version of the company’s product, NeoNavia® biopsy system, clinical studies to demonstrate the benefits of the technology, marketing and launch. More information about the company and the offer will be presented in the prospectus which will be available on the website of the company (www.neodynamics.com), Sedermera Fondkommission (www.sedermera.se) and Spotlight Stock Market (www.spotlightstockmarket) no later than the day before the start of the subscription period. Nordnet Bank AB is acting as Selling Agent in the issue of units, which will also be marketed in Denmark, Norway and Finland. Weiterlesen